Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

CAR T Cell Receptor Immunotherapy Targeting EGFRvIII for Patients With Malignant Gliomas Expressing EGFRvIII

This study has suspended participant recruitment.
Information provided by (Responsible Party):
National Institutes of Health Clinical Center (CC) ( National Cancer Institute (NCI) ) Identifier:
First received: October 6, 2011
Last updated: August 31, 2016
Last verified: August 2016